{"id":"https://openalex.org/W3097083801","doi":"https://doi.org/10.1182/blood-2020-134204","title":"Minimal Residual Disease Eradication with Guadecitabine (SGI-110) in the Post-Transplant Setting","display_name":"Minimal Residual Disease Eradication with Guadecitabine (SGI-110) in the Post-Transplant Setting","publication_year":2020,"publication_date":"2020-11-04","ids":{"openalex":"https://openalex.org/W3097083801","doi":"https://doi.org/10.1182/blood-2020-134204","mag":"3097083801"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-134204","doi":"https://doi.org/10.1182/blood-2020-134204","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-134204","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085076031","display_name":"Bet\u00fcl Oran","orcid":"https://orcid.org/0000-0003-1264-5968","observed_orcids":["https://orcid.org/0000-0003-1264-5968"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Betul Oran","raw_affiliation_strings":["Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034104852","display_name":"Amin Majid Alousi","orcid":"https://orcid.org/0000-0002-2498-8573","observed_orcids":["https://orcid.org/0000-0002-2498-8573"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amin M. Alousi","raw_affiliation_strings":["Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036412023","display_name":"Rohtesh S. Mehta","orcid":"https://orcid.org/0000-0002-8532-544X","observed_orcids":["https://orcid.org/0000-0002-8532-544X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rohtesh S. Mehta","raw_affiliation_strings":["Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035321251","display_name":"David Mar\u00edn","orcid":"https://orcid.org/0000-0003-0812-9346","observed_orcids":["https://orcid.org/0000-0003-0812-9346"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Marin","raw_affiliation_strings":["Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069460930","display_name":"Partow Kebriaei","orcid":"https://orcid.org/0000-0002-8607-9404","observed_orcids":["https://orcid.org/0000-0002-8607-9404"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Partow Kebriaei","raw_affiliation_strings":["Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066894053","display_name":"Uday Popat","orcid":"https://orcid.org/0000-0002-7592-2224","observed_orcids":["https://orcid.org/0000-0002-7592-2224"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Uday R. Popat","raw_affiliation_strings":["Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067252491","display_name":"Amanda Leigh Olson","orcid":"https://orcid.org/0000-0002-1669-0355","observed_orcids":["https://orcid.org/0000-0002-1669-0355"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amanda L. Olson","raw_affiliation_strings":["Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066002932","display_name":"Jessica M McCarty","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jessica M McCarty","raw_affiliation_strings":["Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006002552","display_name":"Jennifer D Ramos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer D Ramos","raw_affiliation_strings":["Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027845051","display_name":"Roland L. Bassett","orcid":"https://orcid.org/0000-0002-4534-2042","observed_orcids":["https://orcid.org/0000-0002-4534-2042"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roland Bassett","raw_affiliation_strings":["Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036678244","display_name":"Harold N Keer","orcid":"https://orcid.org/0000-0003-0753-4921","observed_orcids":["https://orcid.org/0000-0003-0753-4921"]},"institutions":[{"id":"https://openalex.org/I4387155454","display_name":"Astex Pharmaceuticals","ror":"https://ror.org/05fx1fs38","country_code":"US","type":"company","lineage":["https://openalex.org/I114030911","https://openalex.org/I4387155454"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Harold N. Keer","raw_affiliation_strings":["Astex Pharmaceuticals Inc., Pleasanton, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals Inc., Pleasanton, CA","institution_ids":["https://openalex.org/I4387155454"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002347804","display_name":"Peter F. Thall","orcid":"https://orcid.org/0000-0002-7293-529X","observed_orcids":["https://orcid.org/0000-0002-7293-529X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter F Thall","raw_affiliation_strings":["Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5048913229","display_name":"Richard E. Champlin","orcid":"https://orcid.org/0000-0002-4314-5037","observed_orcids":["https://orcid.org/0000-0002-4314-5037"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard E. Champlin","raw_affiliation_strings":["Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.19445453,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":94},"biblio":{"volume":"136","issue":"Supplement 1","first_page":"10","last_page":"11"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.7231000065803528,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.7231000065803528,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":0.25440001487731934,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.002199999988079071,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/guadecitabine","display_name":"guadecitabine","score":0.9789999723434448},{"id":"https://openalex.org/keywords/sgi-110","display_name":"SGI-110","score":0.9739999771118164},{"id":"https://openalex.org/keywords/allogeneic-stem-cell-transplantation","display_name":"allogeneic stem cell transplantation","score":0.906000018119812},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9750000238418579},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.9570000171661377},{"id":"https://openalex.org/keywords/hypomethylating-agents","display_name":"hypomethylating agents","score":0.8849999904632568},{"id":"https://openalex.org/keywords/donor-lymphocyte-infusion","display_name":"donor lymphocyte infusion","score":0.8100000023841858},{"id":"https://openalex.org/keywords/post-transplant-recurrence","display_name":"post-transplant relapse","score":0.6539999842643738},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.8140000104904175},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.49300000071525574},{"id":"https://openalex.org/keywords/graft-versus-host-disease","display_name":"graft-versus-host disease","score":0.593999981880188},{"id":"https://openalex.org/keywords/cytogenetic-relapse","display_name":"cytogenetic relapse","score":0.4050000011920929}],"concepts":[{"id":"https://openalex.org/C2780235182","wikidata":"https://www.wikidata.org/wiki/Q1181878","display_name":"Decitabine","level":5,"score":0.8012397289276123},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7857571840286255},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6373313069343567},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5886390805244446},{"id":"https://openalex.org/C2779823535","wikidata":"https://www.wikidata.org/wiki/Q6865356","display_name":"Minimal residual disease","level":3,"score":0.5588750839233398},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.5426457524299622},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5196458101272583},{"id":"https://openalex.org/C2776239401","wikidata":"https://www.wikidata.org/wiki/Q416451","display_name":"Azacitidine","level":5,"score":0.47850170731544495},{"id":"https://openalex.org/C61943457","wikidata":"https://www.wikidata.org/wiki/Q6046661","display_name":"Interim analysis","level":3,"score":0.46924781799316406},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.32386213541030884},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.29761984944343567},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.2970462441444397},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0856122076511383},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.0},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-134204","doi":"https://doi.org/10.1182/blood-2020-134204","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-134204","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3096368896","https://openalex.org/W3097484998","https://openalex.org/W2907613272","https://openalex.org/W2282189730","https://openalex.org/W2595323673","https://openalex.org/W135063420","https://openalex.org/W2567374876","https://openalex.org/W2532183409","https://openalex.org/W2590047118","https://openalex.org/W2594319486"],"abstract_inverted_index":{"Background:":[0],"Disease":[1],"relapse":[2,297,576,730,850],"remains":[3],"to":[4,50,80,217,231,238,259,268,324,330,414,426,451,457,477,508,534,547,581,655,706,727],"be":[5,269,350],"the":[6,9,55,71,135,160,252,272,276,291,302,418,436,492,569,636,642,671,735,853],"one":[7,501,561],"of":[8,12,40,54,63,75,122,125,162,188,236,246,263,275,282,306,318,335,344,354,438,469,503,526,538,552,645,659,670,679,830],"major":[10],"reasons":[11],"treatment":[13,91,253,493,540,647],"failures":[14],"after":[15,97,154,168,417,472,588,604,630,731],"allogeneic":[16],"stem":[17],"cell":[18,445,461],"transplantation":[19],"(allow-SCT)":[20],"in":[21,77,159,215,387,390,394,432,667,734,852],"AML":[22,396],"and":[23,42,73,116,196,279,310,369,392,443,455,500,577,610,624,657,694,719,815],"MDS":[24,400],"patients":[25],"(pts.).":[26],"Guadecitabineis":[27],"(SGI-110)":[28],"a":[29,37,44,64,332,467,550],"next":[30],"generation":[31],"hypomethylating":[32],"agent":[33],"that":[34,724],"molecularly":[35],"is":[36,266,295,328,716],"dinucleotide":[38],"derivative":[39],"decitabine":[41],"achieves":[43],"more":[45],"effective":[46],"hypomethylation":[47],"activity":[48],"due":[49,580],"extended":[51],"exposure":[52],"window":[53],"active":[56,172],"metabolite":[57],"decitabine.":[58],"We":[59],"present":[60],"interim":[61,136],"results":[62],"single":[65],"arm":[66],"phase":[67],"II":[68],"trial":[69],"evaluating":[70],"efficacy":[72],"safety":[74],"SGI-110":[76,202,237,255,283,307,465,539,646,656,710],"AML/MDS":[78,105],"pts.":[79,106,129,140,228,346,358,397,434,592],"improve":[81],"transplant":[82,98,420],"outcomes.":[83,101],"Methods:":[84],"In":[85],"this":[86],"study,":[87,637],"there":[88,294],"are":[89,157,229,288,725],"3":[90,118,218,664,683],"cohorts":[92],"defined":[93,243],"by":[94,146,410],"disease":[95,179,575],"status":[96],"with":[99,107,112,119,143,254,347,494,521,528,549,596,675,712],"different":[100],"Cohort":[102],"1":[103,395,476,546,556,573,744],"includes":[104,201],"morphological":[108,729],"relapse;":[109],"cohort":[110,117,138],"2":[111,139,391,488,695],"minimal":[113],"residual":[114],"(MRD)":[115],"no":[120,299,495,700],"evidence":[121],"disease.":[123],"As":[124,353],"June":[126,355],"2020,":[127,356],"54":[128],"have":[130,489],"enrolled.":[131],"Herein,":[132],"we":[133],"report":[134],"analyses":[137],"aged":[141],"18-75":[142],"detectable":[144],"MRD":[145,169,348,415,439,473,522,566,589,597,732],"flow":[147],"cytometry":[148],"or":[149,151,174,298,320,322,337,405,665,684,713,832],"cytogenetic":[150],"molecular":[152],"testing":[153],"allo-SCT.":[155,380],"Pts.":[156,248,287,463],"excluded":[158],"presence":[161],"(1)":[163,296],"any":[164],"anti-leukemic":[165],"agents":[166],"used":[167,847],"detection":[170,416,474,733],"(2)":[171,308],"acute":[173],"chronic":[175],"graft":[176],"versus":[177],"host":[178],"(GvHD),":[180],"(3)":[181,316],"uncontrolled":[182],"systemic":[183,189],"infection":[184],"(4)":[185],"Concurrent":[186],"use":[187],"immune":[190],"suppressive":[191],"other":[192],"than":[193],"calcineurin":[194],"inhibitors":[195],"sirolimus.":[197],"The":[198,227,536,738],"study":[199,292,509,707,739],"intervention":[200],"given":[203,256,270,711],"as":[204,244,257,339],"40":[205],"mg/m2/day":[206],"subcutaneously":[207],"for":[208,453,459,486,614,622,626,849],"5":[209,702],"consecutive":[210],"days":[211,214,423,471],"every":[212],"28":[213,367,425],"addition":[216],"planned":[219,267],"donor":[220],"lymphocyte":[221],"infusions":[222],"(DLI)":[223],"if":[224,284,293],"clinically":[225,285],"feasible.":[226,286],"allowed":[230],"receive":[232],"maximum":[233,343],"6":[234,304,376,399,402,518,548,570],"cycles":[235,262,281,305,541,644],"achieve":[239],"response":[240,250,300,333,496,512,520,543,595,605,631,722],"which":[241],"was":[242,361,385,421,430,447,514,607,612,620,699,846],"eradication":[245,523],"MRD.":[247],"achieving":[249,565],"continue":[251],"maintenance":[258],"complete":[260],"12":[261],"treatment.":[264],"DLI":[265,562,715],"on":[271,784,790,796,826],"6th":[273,280],"day":[274],"2nd,":[277],"4th":[278],"taken":[289],"off":[290],"within":[301,466],"first":[303],"related":[309,507,583,674],"unexpected":[311],"serious":[312],"adverse":[313,386],"events":[314],"(AEs)":[315],"withdrawal":[317],"consent":[319],"death":[321],"lost":[323],"follow":[325],"up.":[326],"Study":[327],"designed":[329],"take":[331],"probability":[334,525],".20":[336],"larger":[338],"considered":[340],"promising.":[341],"A":[342],"25":[345],"will":[349],"treated.":[351],"Results:":[352],"17":[357,374,470,481],"enrolled;":[359],"M/F":[360],"6/11,":[362],"median":[363,441,468,551],"age":[364],"63":[365],"(range":[366],"to70)":[368],"11":[370],"had":[371,377,403,574,594],"AML.":[372],"Of":[373,398,480,516,568,649],"pts.,":[375,401,482],"their":[378],"second":[379],"European":[381],"LeukemiaNet":[382],"risk":[383,408],"category":[384],"8,":[388],"intermediate":[389],"favorable":[393],"poor":[404,407],"very":[406],"cytogenetics":[409],"revised-IPSS.":[411],"Median":[412],"time":[413,437],"last":[419],"94":[422],"(range,":[424,449,475],"504":[427],"days).":[428,479],"Chimerism":[429],"checked":[431],"16":[433],"at":[435,559,602,628],"detection;":[440],"T":[442,454],"myeloid":[444,460],"chimerism":[446],"100%":[448,452,458,608,621],"35%":[450],"24%":[456],"lineages).":[462],"started":[464],"58":[478],"14":[483],"were":[484,653,662,673,688,692,696],"evaluable":[485],"response;":[487],"been":[490,741],"undergoing":[491],"evaluation":[497,513],"yet":[498],"done":[499],"died":[502,579],"respiratory":[504],"complications":[505],"not":[506],"drug":[510],"before":[511,542,564],"possible.":[515],"14,":[517],"achieved":[519],"(posterior":[524],"response=41.3%":[527],"95%":[529],"credible":[530],"interval":[531],"(CI)":[532],"18.0%":[533],"65.3%).":[535],"number":[537],"varied":[544],"from":[545],"3.":[553],"All":[554],"but":[555],"responders":[557,623],"received":[558],"least":[560],"infusion":[563],"eradication.":[567],"responders,":[571],"only":[572],"another":[578],"GvHD":[582],"complications,":[584],"both":[585],"20":[586],"months":[587],"detection.":[590],"For":[591],"who":[593],"eradication,":[598],"relapse-free":[599],"survival":[600],"(RFS)":[601],"1-year":[603,629],"determination":[606,632],"(95%CI=21%-69.6%)":[609],"it":[611],"0%":[613,625],"non-responders":[615,627],"(Figure":[616,633],"1a).":[617],"Similarly,":[618],"OS":[619],"1b).":[634],"During":[635],"130":[638],"AEs":[639,672,681],"observed":[640,704],"during":[641],"53":[643],"applied.":[648],"130,":[650],"108":[651,660],"(83%)":[652],"attributable":[654,705],"70":[658,680],"(65%)":[661],"grade":[663,682,701],"higher":[666],"severity.":[668],"Most":[669],"bone":[676],"marrow":[677],"suppression;":[678],"higher,":[685],"23":[686],"(33%)":[687],"thrombocytopenia,":[689],"15":[690],"(21%)":[691],"neutropenia,":[693],"anemia.":[697],"There":[698],"AE":[703],"drug.":[708],"Conclusion:":[709],"without":[714],"well":[717],"tolerated":[718],"yields":[720],"encouraging":[721],"rates":[723],"durable":[726],"prevent":[728],"post-transplant":[736,854],"setting.":[737,855],"has":[740],"ongoing.":[742],"Figure":[743],"Disclosures":[745],"Oran:":[746],"ASTEX:":[747],"Research":[748,752,758,763,766,769,773,777,801,804,807],"Funding;":[749,753,759,767,770,805],"Arog":[750],"Pharmaceuticals:":[751],"Celgene:":[754],"Consultancy.":[755],"Alousi:Incyte:":[756],"Honoraria,":[757],"Alexion:":[760],"Honoraria;":[761],"Therakos:":[762],"Funding.":[764,774,808],"Mehta:Kadmon:":[765],"Incyte:":[768],"CSL":[771],"Behring:":[772],"Kebriaei:Amgen:":[775],"Other:":[776,782,788,794,800],"Support;":[778],"Jazz:":[779],"Consultancy;":[780,817,822,836,838],"Kite:":[781],"Served":[783,789,795],"advisory":[785,791,797,833],"board;":[786,792,798],"Novartis:":[787,806],"Pfizer:":[793],"Ziopharm:":[799],"Support.":[802],"Popat:Bayer:":[803],"Keer:Astex":[809],"Pharmaceuticals,":[810],"Inc.:":[811],"Current":[812],"Employment.":[813],"Champlin:Johnson":[814],"Johnson:":[816],"Genzyme:":[818],"Speakers":[819],"Bureau;":[820],"Actinium:":[821],"DKMS":[823],"America:":[824],"Membership":[825],"an":[827],"entity's":[828],"Board":[829],"Directors":[831],"committees;":[834],"Cytonus:":[835],"Omeros:":[837],"Takeda:":[839],"Patents":[840],"&":[841],"Royalties.":[842],"OffLabel":[843],"Disclosure:":[844],"Guadecitabine":[845],"off-label":[848],"prevention":[851]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2020-11-09T00:00:00"}